reports
Update: Moving closer towards Abili-T data in SPMS
The Abili-T Phase IIb study evaluating Opexa’s Tcelna immunotherapy as a treatment for secondary progressive MS (SPMS) is nearing completion. The firm is fully funded to Phase IIb data, which are expected in early Q416 and, if positive, could sharply increase investor and stakeholder interest. Merck, the marketer of MS drug Rebif (interferon beta-1a), has an option to in-license Tcelna in MS. Our rNPV is $37.7m (vs $35.1m previously); after including $7.0m Q216 net cash, this gives an equity v...
Update: Restructuring sharpens focus on Tcelna data
On 2 March Opexa announced it has embarked on a restructuring initiative to prioritize its spending towards completing the ongoing 190-patient Abili-T Phase II study of lead candidate Tcelna in secondary progressive multiple sclerosis (SPMS). The company has reduced its overall headcount by about 30%, but this does not affect the Abili-T study timelines, for which data are expected in early Q416. The restructuring lengthens the company’s financial runway into Q117 (vs prior guidance of Q416), ...
Update: Restructuring sharpens focus on Tcelna data
On 2 March Opexa announced it has embarked on a restructuring initiative to prioritize its spending towards completing the ongoing 190-patient Abili-T Phase II study of lead candidate Tcelna in secondary progressive multiple sclerosis (SPMS). The company has reduced its overall headcount by about 30%, but this does not affect the Abili-T study timelines, for which data are expected in early Q416. The restructuring lengthens the company’s financial runway into Q117 (vs prior guidance of Q416), ...
Initiation: Personalized immunotherapy for MS
Opexa’s Tcelna immunotherapy is advancing in Phase IIb studies in secondary progressive MS (SPMS), with data expected in H216. The firm is fully funded to Phase II data which, if positive, could sharply increase investor and stakeholder interest. Merck KGaA has an option to in-license Tcelna in MS. Opexa is also developing OPX-212 in neuromyelitis optica (NMO), a rare autoimmune disorder leading to vision loss and paralysis. Opexa plans to file an IND and start a Phase I/II study in H116. Our ...
QuickView: Personalised MS immunotherapy
Opexa is funded through to the H216 readout of its Phase IIb Abili-T study of Tcelna in secondary progressive multiple sclerosis (SPMS). SPMS affects 30-45% of the approximately two million worldwide MS patients and an approved treatment could generate more than $5bn in US sales.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.